Please login to the form below

Not currently logged in
Email:
Password:

Natco Pharma

This page shows the latest Natco Pharma news and features for those working in and with pharma, biotech and healthcare.

Teva faces early rival to longer-acting Copaxone in US

Teva faces early rival to longer-acting Copaxone in US

the importance Copaxone (glatiramer acetate) has to the Israeli pharma group’s finances. ... The approval and launch is also big news for Indian company Natco Pharma, which partnered with Mylan on developing the generic and will share profits on sales.

Latest news

  • India turns down patent on Gilead's Sovaldi India turns down patent on Gilead's Sovaldi

    Last year, Sovaldi's Indian intellectual property (IP) also faced a "pre-grant" objection from domestic pharma company Natco as well as the New York-based Initiative for Medicines, Access &Knowledge ... The Indian ruling suggests other drugmakers like

  • BMS says it defends Sprycel patent in India BMS says it defends Sprycel patent in India

    BDR had been trying to secure a compulsory license to overturn BMS' 2010 Indian patent on Sprycel on the grounds of public need, a strategy which allowed Natco Pharma to start ... Towards the end of last year court documents suggested Natco was no longer

  • Bayer fails to overturn Nexavar compulsory licence in India Bayer fails to overturn Nexavar compulsory licence in India

    Natco Pharma allowed to sell cut-price version of cancer drug. Bayer's first attempt at overturning a compulsory license in India for its cancer drug Nexavar was knocked back yesterday ... The Intellectual Property Appellate Board (IPAB) upheld the

  • India could hit Roche and BMS with compulsory licences India could hit Roche and BMS with compulsory licences

    The first compulsory licence in India was introduced last year for Bayer's liver cancer drug Nexevar (sorefinib), allowing Natco Pharma to sell a copy of the treatment that was 95 ... It is a very good move and will not just benefit Indians but possibly

More from news
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics